NAD < sup > + < /sup > metabolism and eye diseases: current status and future directions

Mol Biol Rep. 2023 Aug 4. doi: 10.1007/s11033-023-08692-y. Online ahead of print.ABSTRACTCurrently, there are no truly effective treatments for a variety of eye diseases, such as glaucoma, age-related macular degeneration (AMD), and inherited retinal degenerations (IRDs). These conditions have a significant impact on patients' quality of life and can be a burden on society. However, these diseases share a common pathological process of NAD+ metabolism disorders. They are either associated with genetically induced primary NAD+ synthase deficiency, decreased NAD+ levels due to aging, or enhanced NAD+ consuming enzyme activity during disease pathology. In this discussion, we explore the role of NAD+ metabolic disorders in the development of associated ocular diseases and the potential advantages and disadvantages of various methods to increase NAD+ levels. It is essential to carefully evaluate the possible adverse effects of these methods and conduct a more comprehensive and objective assessment of their function before considering their use.PMID:37540459 | DOI:10.1007/s11033-023-08692-y
Source: Molecular Biology Reports - Category: Molecular Biology Authors: Source Type: research